4
Changes in Ownership
Nurix Therapeutics, Inc. Filed Acc 0001209191-23-043975
Chief Scientific Officer sold 1,884 shares at $9.65 ($18,189)
- Chief Scientific Officer acquired 5,207 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Hansen Gwenn · Chief Scientific Officer
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-07-30 | Exercise or conversion : show line 1 in the form | +3,207 | 29,839 | D | ||
| 2023-07-30 | Exercise or conversion : show line 2 in the form | +2,000 | 31,839 | D | ||
| 2023-07-31 | Sale : show line 3 in the form | −1,884 | $9.65 | $18,189 | 29,955 | D |
| Open-market sales · 1,884 sh · avg $9.65 · $18,189 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2023-07-30 | Exercise or conversion : show line 4 in the form Restricted Stock Units | −3,207 | 32,068 | D |
| 2023-07-30 | Exercise or conversion : show line 5 in the form Restricted Stock Units | −2,000 | 22,000 | D |
Loading xslF345X05/doc4.xml…